Nota de idioma: o chrome desta página está em português; o corpo longo abaixo permanece em inglês para preservar a precisão das fontes.
Tirzepatide
Also indexed as Mounjaro · Zepbound · LY3298176 · GIP / GLP-1 receptor agonist
Tirzepatide is a single peptide designed to activate both GIP and GLP-1 receptors. Lilly studied it as LY3298176 before approvals created separate product and label contexts.
Last reviewed 2026-09-07 · education only
O que aparece na literatura
It engages GIP and GLP-1 receptors, two incretin pathways involved in glucose regulation and appetite biology. The dual-receptor description explains the molecule; it does not imply that every marketplace name is the same product.
History & development
- 2018
A phase 2 randomized trial published the early clinical study of LY3298176, the dual GIP/GLP-1 agonist later named tirzepatide.
Source: The Lancet phase 2 trial ↗
- 2022
The FDA approved Mounjaro (tirzepatide) for its labeled type 2 diabetes indication.
Source: DailyMed: Mounjaro label ↗
- 2023
The FDA approved Zepbound (tirzepatide) as a separate product with a chronic weight-management label.
Source: DailyMed: Zepbound label ↗
Approved brands & pathway
Mounjaro
United StatesFDA-approved prescription product
Tirzepatide product with a type 2 diabetes label; read the current label.
Open DailyMed label search ↗Zepbound
United StatesFDA-approved prescription product
Tirzepatide product with an obesity-related label; read the current label.
Open DailyMed label search ↗Entradas de evidência
Tema: Obesity · GLP-1/GIP · Categoria: Obesity
Tirzepatide
O que a fonte sustenta
Randomized phase 3 weight-loss research
SURMOUNT-1 reported weight outcomes for a defined phase 3 population with obesity or overweight and no diabetes.
Limite: This was not a head-to-head comparison in the cited trial; read population, dose and follow-up before generalizing.
Fonte: SURMOUNT-1 · PubMed Ler fonte ↗
Tema: Diabetes · cardiovascular outcomes · Categoria: Diabetes
Tirzepatide
O que a fonte sustenta
Diabetes cardiovascular safety evidence
SURPASS-4 compared tirzepatide with insulin glargine in adults with type 2 diabetes at increased cardiovascular risk and reported clinical outcomes during follow-up.
Limite: The study was not designed as a definitive superiority cardiovascular-outcomes trial; association is not a personal treatment recommendation.
Fonte: SURPASS-4 · The Lancet Ler fonte ↗
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
Naming curiosities & useful distinctions
- LY3298176 is the development code; tirzepatide is the generic name; Mounjaro and Zepbound are product names.
- The GIP/GLP-1 shorthand describes receptor activity, not a blend of two separate drugs.
A dual agonist
Lilly's comparison page distinguishes tirzepatide from retatrutide by receptor profile: two incretin-related receptors versus three hormone receptors for retatrutide.
Nomes no registro
Developer
Eli Lilly and Company
Lilly developed tirzepatide and identifies LY3298176 as its earlier development code.